At the Company:                                  At In-Site Communications, Inc.
Ben J. Pothast                                   Lisa Carlton-Wilson
Chief Financial Officer                          Investor Relations
(847) 279-6100                                  (212) 759-3929


FOR IMMEDIATE RELEASE


                     AKORN, INC. STOCK DELISTED FROM NASDAQ


BUFFALO GROVE, IL, JUNE 25, 2002 -- AKORN, INC. (NASDAQ: AKRNE) today announced
that it was informed late yesterday by Nasdaq that a Nasdaq Listing
Qualifications Panel has issued an order delisting Akorn securities from the
Nasdaq National Market effective at the opening of business on June 25, 2002.

This action taken by Nasdaq is due to the fact that, as previously disclosed,
the Company does not comply with the Nasdaq report filing requirements with
respect to its Form 10-K filing with the SEC for the year ended December 31,
2001. Specifically, the 10-K for this period was filed with unaudited financial
statements. As the Company has previously explained, its independent auditors
have been unwilling to issue an audit opinion on the Company's consolidated
financial statements as of December 31, 2001 because the staff of the SEC has
the informed the Company of a proposed enforcement action, alleging the
Company's accounts receivable were overstated as of December 31, 2000, which
could result in a restatement of certain 2000 and 2001 financial statements.

Akorn intends to appeal this decision by the Nasdaq Listing Qualifications
Panel. During this appeal process, the Company will attempt to work with the SEC
and the Company's auditors to resolve the restatement issues that have been
raised so as to allow it to obtain audited financial statements that comply with
the Nasdaq report filing requirements. There can be no assurance, however, when
or if such resolution will occur. The Company's securities will be traded on the
Pink Sheets, as soon as possible, until the above matters are resolved.

ABOUT AKORN, INC.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals, and
markets and distributes an extensive line of pharmaceuticals and ophthalmic
surgical supplies and related products.

The information contained in this news release, other than historical
information, consists of forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from those
described in such statements. Such statements, including, but not limited to,
the timing of acquiring and developing new products, of bringing them on line
and deriving revenues and profits from them, as well as the effects of those
revenues and profits on the Company's margin and financial position are
uncertain because many of the factor affecting the timing of those items are
beyond the Company's control. Such statements are based on management's current
expectations, but actual results may differ materially due to various factors
including risks and uncertainties mentioned or referred to in this press release
or in the filings the Company makes with the Securities and Exchange Commission
including it annual reports on Form 10-K and its quarterly reports on Form 10-Q.